2 weeks Ago By ABMN Staff
Lynx1 Capital Management LP increased its stake in shares of Passage Bio, Inc. ( NASDAQ:PASG – Free Report ) by 4.4% during the second quarter, according to the company in its most recent disclosure with the SEC.
The institutional investor owned 5,057,629 shares of the company’s stock after buying an additional 211,758 shares during the quarter. Passage Bio comprises 1.5% of Lynx1 Capital Management LP’s holdings, making the stock its 9th largest position.
Lynx1 Capital Management LP owned 8.19% of Passage Bio worth $4,017,000 as of its most recent filing with the SEC. Several other hedge funds have also made changes to their positions in the company.
Vanguard Group Inc. grew its position in Passage Bio by 2.6% in the first quarter.
Vanguard Group Inc. now owns 2,071,538 shares of the company’s stock worth $2,797,000 after acquiring an additional 52,656 shares during the period. Affinity Asset Advisors LLC acquired a new position in shares of Passage Bio in the 1st quarter valued at $357,000.
Acadian Asset Management LLC grew its holdings in shares of Passage Bio by 59.0% during the 1st quarter. Acadian Asset Management LLC now owns 961,271 shares of the company’s stock worth $1,296,000 after purchasing an additional 356,593 shares during the period.
Finally, Pale Fire Capital SE increased its position in shares of Passage Bio by 489.1% during the 4th quarter. Pale Fire Capital SE now owns 581,257 shares of the company’s stock worth $587,000 after purchasing an additional 482,595 shares during the last quarter.
Hedge funds and other institutional investors own 53.48% of the company’s stock. Passage Bio Price Performance Shares of PASG opened at $0.
64 on Friday. Passage Bio, Inc. has a fifty-two week low of $0.
58 and a fifty-two week high of $1.79. The firm’s 50 day moving average price is $0.
77 and its 200 day moving average price is $1.05. The company has a market cap of $39.
53 million, a P/E ratio of -0.42 and a beta of 1.19.
Insider Buying and Selling In other news, major shareholder Orbimed Advisors Llc sold 63,100 shares of Passage Bio stock in a transaction on Monday, September 16th. The shares were sold at an average price of $0.74, for a total transaction of $46,694.
00. Following the completion of the sale, the insider now directly owns 7,970,900 shares of the company’s stock, valued at approximately $5,898,466. The transaction was disclosed in a filing with the SEC, which is available through the SEC website .
4.30% of the stock is owned by insiders. Analyst Upgrades and Downgrades Separately, Rodman & Renshaw began coverage on shares of Passage Bio in a research report on Tuesday, September 3rd.
They issued a “buy” rating and a $7.00 target price on the stock. View Our Latest Analysis on Passage Bio Passage Bio Profile ( Free Report ) Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases.
It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. Recommended Stories Want to see what other hedge funds are holding PASG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Passage Bio, Inc.
( NASDAQ:PASG – Free Report ). Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter .
.
